These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36204383)

  • 1. Gut microbiota-mitochondrial inter-talk in non-alcoholic fatty liver disease.
    Zhang Q; Xing W; Wang Q; Tang Z; Wang Y; Gao W
    Front Nutr; 2022; 9():934113. PubMed ID: 36204383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
    Jayachandran M; Qu S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Huang Y; Cao J; Zhu M; Wang Z; Jin Z; Xiong Z
    Microbiol Spectr; 2024 Apr; 12(4):e0339323. PubMed ID: 38411057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children.
    Luo J; Luo M; Kaminga AC; Wei J; Dai W; Peng Y; Zhao K; Duan Y; Xiao X; Ouyang S; Yao Z; Liu Y; Pan X
    Microbiol Spectr; 2024 Apr; 12(4):e0523022. PubMed ID: 38445874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
    Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease, diet and gut microbiota.
    Finelli C; Tarantino G
    EXCLI J; 2014; 13():461-90. PubMed ID: 26417275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
    Tokuhara D
    Front Nutr; 2021; 8():700058. PubMed ID: 34250000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiota-Mitochondria Inter-Talk: A Potential Therapeutic Strategy in Obesity and Type 2 Diabetes.
    Vezza T; Abad-Jiménez Z; Marti-Cabrera M; Rocha M; Víctor VM
    Antioxidants (Basel); 2020 Sep; 9(9):. PubMed ID: 32927712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial Metabolites: Critical Regulators in NAFLD.
    Dai X; Hou H; Zhang W; Liu T; Li Y; Wang S; Wang B; Cao H
    Front Microbiol; 2020; 11():567654. PubMed ID: 33117316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.
    Hrncir T; Hrncirova L; Kverka M; Hromadka R; Machova V; Trckova E; Kostovcikova K; Kralickova P; Krejsek J; Tlaskalova-Hogenova H
    Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.